Linked Life Data

2645036

Source:http://linkedlifedata.com/resource/pubmed/id/2645036

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
1989-4-5
pubmed:abstractText
Cisplatin is a backbone of any combination chemotherapy currently in use for the treatment for nonseminomatous germ cell tumors. Recently new platinum analogs with lower toxicity have been developed. The antitumor activity of two analogs, carboplatin (JM8) and iproplatin (JM9) was compared to cisplatin in vitro and in vivo. The 3thymidine incorporation in three established human testicular cancer cell lines was significantly stronger inhibited by cisplatin than by JM8 or JM9. Cisplatin showed a significantly stronger antitumor activity against heterotransplanted human testicular cancer cell lines in the nude mouse than JM8 or JM9 when given at equitoxic doses. Although both analogs only moderately retarded the tumor growth, cisplatin produced a significant reduction of tumor volume in three of four cell lines. From these data it is concluded that the antitumor activity of cisplatin may be significantly superior to JM8 and JM9, and results of preclinical investigations should be awaited before replacement of cisplatin by JM8 or JM9 in the treatment of nonseminomatous germ cell tumors can be considered.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0008-543X
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
63
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1079-83
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1989
pubmed:articleTitle
Comparison of the antitumor activity of cisplatin, carboplatin, and iproplatin against established human testicular cancer cell lines in vivo and in vitro.
pubmed:affiliation
Medical School Hannover, Department of Hematology, Oncology, West Germany.
pubmed:publicationType
Journal Article, Comparative Study